ARIAD's Regulated Cell Therapy and Stem Cell Therapy Products Featured in Techvest Investment Conference.Business Editors CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2000 Tissue repair, replacement and regeneration products highlighted ARIAD ARIAD Allison Research Index of Art and Design Pharmaceuticals, Inc. (Nasdaq: ARIA) announced that its ARGENT ar·gent n. 1. Heraldry The metal silver, represented by the color white. 2. Archaic Silver or something resembling it. (TM) cell therapy and stem cell therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs products are highlighted today in Techvest's second annual conference on tissue repair, replacement and regeneration. ARIAD's products feature dose-dependent, small-molecule control of cell survival and cell growth, enhancing the safety and efficacy of cell therapies. The most advanced ARGENT program, ARIAD's regulated cell therapy to treat graft-vs-host disease, is in Phase 2 clinical development in patients undergoing allogeneic allogeneic /al·lo·ge·ne·ic/ (-je-ne´ik) 1. having cell types that are antigenically distinct. 2. in transplantation biology, denoting individuals (or tissues) that are of the same species but antigenically bone marrow transplantation Bone Marrow Transplantation Definition The bone marrow—the sponge-like tissue found in the center of certain bones—contains stem cells that are the precursors of white blood cells, red blood cells, and platelets. . The ARGENT gene regulation technology also is being used in the development of stem cell therapy products, providing a cell-growth switch that allows in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. control of the growth and differentiation of specific cell types, such as blood, liver, muscle and nerve cells. Preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. demonstrate that stem cells and primary cells can be regulated in vivo by ARIAD's small-molecule drugs. ARIAD and its collaborators are developing innovative treatments for genetic blood diseases, hepatic failure, congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. , and neurodegenerative diseases based on these findings. Additional information on the investment conference can be obtained at Techvest's website (www.tissueconference.com). ARIAD Pharmaceuticals, Inc. (www.ariad.com) is a leader in the discovery and development of gene therapy, cell therapy, stem cell therapy and protein therapy products featuring dose-dependent regulation by small-molecule drugs, as well as small-molecule inhibitors of signal transduction. Some of the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including, but are not limited to, the risks and uncertainties regarding the Company's preclinical studies, the ability of the Company to conduct clinical trials of its products and the results of such trials, as well as risks and uncertainties relating to economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on our collaborators and other factors under the heading "Cautionary Statement Regarding Forward-Looking Statements" in ARIAD's Annual Report on Form 10-K for the fiscal year ended December 31, 1999 filed with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion